These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 1116124)

  • 1. Effect of antimyeloma cell antiserum on immunological enhancement.
    Hosokawa M; Mihich E; Watanabe T; Pressman D
    Cancer Res; 1975 Mar; 35(3):591-5. PubMed ID: 1116124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
    Adler A; Altbaum I
    J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fast- and slow-growing transplantable tumors derived from spontaneous mammary tumors of the DBA/2 Ha-DD mouse.
    Hosokawa M; Orsini F; Mihich E
    Cancer Res; 1975 Oct; 35(10):2657-62. PubMed ID: 1157040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma.
    Morecki S; Yacovlev E; Gelfand Y; Uzi I; Slavin S
    J Immunother; 2001; 24(2):114-21. PubMed ID: 11265768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer immunity after treatment of Ehrlich tumor with diphtheria toxin.
    Buzzi S; Buzzi L
    Cancer Res; 1974 Dec; 34(12):3481-6. PubMed ID: 4429964
    [No Abstract]   [Full Text] [Related]  

  • 6. Differential antigenic expression of the DBA/2 lymphoma L1210 and its sublines: cross-reactivity with C3H mammary tumors as defined by syngeneic monoclonal antibodies.
    Rapp L; Fuji H
    Cancer Res; 1983 Jun; 43(6):2592-9. PubMed ID: 6342755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An experimental model for evaluation of factors in tumor escape from immunological attack.
    Yutoku M; Fuji H; Grossberg AL; Pressman D
    Cancer Res; 1975 Mar; 35(3):734-9. PubMed ID: 1116132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is immunosuppression at the tumor site mechanism of evasion of a systemic response?
    Karakousis CP; Sharma S; Brooks SP
    J Med; 2003; 34(1-6):3-14. PubMed ID: 17682306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors.
    Knisely TL; Luckenbach MW; Fischer BJ; Niederkorn JY
    J Immunol; 1987 Jun; 138(12):4515-23. PubMed ID: 3108394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro studies of allotype suppression in mice.
    Jacobson EB
    Eur J Immunol; 1973 Oct; 3(10):619-24. PubMed ID: 4765243
    [No Abstract]   [Full Text] [Related]  

  • 11. Cell population kinetics of fast- and slow-growing transplantable tumors derived from spontaneous mammary tumors of the DBA/2 Ha-DD mouse.
    Pavelic ZP; Porter CW; Allen LM; Mihich E
    Cancer Res; 1978 Jun; 38(6):1533-8. PubMed ID: 647669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammary tumor immune enhancement in mice by local hyperemia.
    Vaage J
    Cancer Res; 1986 Jan; 46(1):386-9. PubMed ID: 3940204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unresponsiveness to Mlsa induced in newborn Mlsb mice by maternal preimmunization.
    Matossian-Rogers A; DeGiorgi L
    Immunology; 1991 Feb; 72(2):219-25. PubMed ID: 1826669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors.
    Townsend SE; Su FW; Atherton JM; Allison JP
    Cancer Res; 1994 Dec; 54(24):6477-83. PubMed ID: 7527298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune status of autochthonous and adoptively protected mice toward spontaneous and chemically induced tumors.
    Basombrío MA; Prehn RT
    Cancer Res; 1972 Nov; 32(11):2545-50. PubMed ID: 5082598
    [No Abstract]   [Full Text] [Related]  

  • 16. Effective anti-tumor immunity induced in mice by a two-step vaccination protocol.
    Martino A; Vismara D; Cicconi R; Delpino A; Ivanyi J; Colizzi V; Cassol M; Fraziano M; Piselli P
    In Vivo; 2001; 15(5):425-8. PubMed ID: 11695241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active immunological enhancement of sarcoma 180 in splenectomized Swiss mice.
    Dosne Pasqualini C; Colmerauer ME
    Biomedicine; 1976 Jul; 25(6):202-4. PubMed ID: 963183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apparent lack of immunogenicity of estrogen-induced testicular Leydig cell tumors in BALB/c mice.
    Huseby RA; Page RH
    Cancer Res; 1982 Nov; 42(11):4332-8. PubMed ID: 6751521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surrogate tumor antigen vaccination induces tumor-specific immunity and the rejection of spontaneous metastases.
    Lewis JD; Shearer MH; Kennedy RC; Bright RK
    Cancer Res; 2005 Apr; 65(7):2938-46. PubMed ID: 15805297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulating factor derived from a murine mammary tumor.
    Fu YX; Watson G; Jimenez JJ; Wang Y; Lopez DM
    Cancer Res; 1990 Jan; 50(2):227-34. PubMed ID: 2136804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.